|Mr. Daniel Tassé||CEO & Director||1.14M||N/A||1960|
|Mr. Sébastien Robitaille||Chief Financial Officer||339.08k||N/A||1970|
|Dr. Pharis Mohideen||Chief Medical Officer||690.3k||N/A||1965|
|Mr. Pascal Wotling||Chief Technical Operations Officer & Chief Quality Officer||N/A||N/A||N/A|
|Anne Pollak||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Michele F. Robertson||Chief Legal Officer||N/A||N/A||N/A|
|Joseph Becker||VP of Global Corp. Communications||N/A||N/A||N/A|
|Ms. Caroline Daniere||Chief HR Officer & Chief of Staff||N/A||N/A||1975|
|Dr. Wence Agbotounou||Chief Clinical Trial Officer & Sr. VP||N/A||N/A||N/A|
|Ms. Lucie Mondoulet||Sr. VP & Deputy CSO||N/A||N/A||N/A|
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBV Technologies S.A.’s ISS governance QualityScore as of 1 June 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 1; Compensation: 10.